PUBLISHER: BCC Research | PRODUCT CODE: 1895160
PUBLISHER: BCC Research | PRODUCT CODE: 1895160
The global market for advanced drug delivery systems (ADDS) is estimated to grow from $299.6 billion in 2025 and projected to reach $487.4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.
The North American market for ADDS is estimated to grow from $165.6 billion in 2025 and projected to reach $269.9 billion by the end of 2030, at a CAGR of 10.3% from 2025 to 2030.
The Asia-Pacific market for ADDS is estimated to grow from $38.3 billion in 2025 and projected to reach $64.1 billion by the end of 2030, at a CAGR of 10.9% from 2025 to 2030.
The current report provides detailed information on advanced drug delivery systems (ADDS). This report analyzes the market trends of ADDS with data from 2024, estimates for 2025, projections of compound annual growth rates through 2030 (forecast period 2025-2030) and regional markets of advanced drug delivery systems. This report highlights the advanced drug delivery systems' current and future market potential of ADDS and provides a detailed analysis of the competitive environment. The report covers regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market shares of leading manufacturers.
The market is segmented by routes of administration into enteral, parenteral, nasal, transdermal, implant, ophthalmic and other routes. Enteral routes are sub-segmented into oral, sublingual, buccal and rectal. Parenteral routes are sub-segmented into intravenous, subcutaneous and intramuscular. The respiratory route is sub-segmented into intranasal and inhalational.
The market is segmented by technology into targeted-release drug delivery, extended-release drug delivery, delayed-release drug delivery, immediate-release drug delivery and pulsatile-release drug delivery. Based on vehicle/carriers, the market scope is segmented into nanoparticles, monoclonal antibodies, liposomes, polymer therapeutics, prodrugs, microparticles and others.
The market is segmented by application into oncological, cardiovascular, respiratory, autoimmune, inflammatory, metabolic, as well as gastrointestinal disorders, ophthalmic and other therapeutics.
The market has been segmented into significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment will include a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, data will be provided for 2024 as the base year, with forecast values for 2025 through 2030.
The report aims to: